Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Receivables - Net (2018 - 2025)

Historic Receivables - Net for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $4.8 billion.

  • Takeda Pharmaceutical's Receivables - Net rose 224.66% to $4.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.8 billion, marking a year-over-year increase of 224.66%. This contributed to the annual value of $4.7 billion for FY2025, which is 49.07% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Receivables - Net stood at $4.8 billion, which was up 224.66% from $4.7 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's Receivables - Net's 5-year high stood at $7.7 billion during Q3 2021, with a 5-year trough of -$80.8 million in Q1 2022.
  • In the last 5 years, Takeda Pharmaceutical's Receivables - Net had a median value of $4.8 billion in 2023 and averaged $4.9 billion.
  • In the last 5 years, Takeda Pharmaceutical's Receivables - Net crashed by 10109.21% in 2022 and then skyrocketed by 821035.58% in 2024.
  • Takeda Pharmaceutical's Receivables - Net (Quarter) stood at $6.3 billion in 2021, then decreased by 20.46% to $5.0 billion in 2022, then decreased by 3.22% to $4.8 billion in 2023, then dropped by 3.42% to $4.7 billion in 2024, then grew by 2.25% to $4.8 billion in 2025.
  • Its Receivables - Net stands at $4.8 billion for Q4 2025, versus $4.7 billion for Q3 2025 and $4.6 billion for Q2 2025.